Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival

References

• Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother. 2002;56:223–234.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:57–65.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.
   PubMed Web of Science ®Google Scholar
• Oracki SA, Walker JA, Hibbs ML, et al. Plasma cell development and survival. Immunol Rev. 2010;237:140–159.
   PubMed Web of Science ®Google Scholar
• Mylin AK, Rasmussen T, Johansen JS, et al. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur J Haematol. 2006;77:416–424.
   PubMed Web of Science ®Google Scholar
• Sawamura M, Murakamp IH. Tumor necrosis factor-α and interleukin 4 in myeloma cell precursor differentiation. 1996;21:31–36.
   Google Scholar
• Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer. 2003;97:2440–2452.
   PubMed Web of Science ®Google Scholar
• Klein B, Tarte K, Jourdan M, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol. 2003;78:106–113.
   PubMed Web of Science ®Google Scholar
• Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997;349:170–173.
   PubMed Web of Science ®Google Scholar
• Howell WM, Rose-Zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr. 2007;137:194S–199S.
   PubMed Web of Science ®Google Scholar
• Vangsted AJ, Klausen TW, Gimsing P, et al. A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. Haematologica. 94:1274–1281.
   PubMed Web of Science ®Google Scholar
• Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma I: effect on risk of multiple myeloma. Eur J Haematol. 2012;88:8–30.
   PubMed Web of Science ®Google Scholar
• Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma II: association with effect of treatment. Eur J Haematol. 2012;88:93–117.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Adamson PJ, Mensah FK, et al. Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol. 2005y;129:358–365.
   PubMed Web of Science ®Google Scholar
• Davies FE, Rollinson SJ, Rawstron AC, et al. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. JCO. 2000;18:2843–2851.
   PubMed Web of Science ®Google Scholar
• Zheng C, Huang DR, Bergenbrant S, et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol. 2000;109:39–45.
   PubMed Web of Science ®Google Scholar
• Kádár K, Kovács M, Karádi I, et al. Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res. 2008;32:1499–1504.
   PubMed Web of Science ®Google Scholar
• Zheng C, Huang D, Liu L, et al. Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int J Cancer. 2001;95:184–188.
   PubMed Web of Science ®Google Scholar
• Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet. 2005;6:287–298.
   PubMed Web of Science ®Google Scholar
• Gilbert-Diamond D, Moore JH. Current Protocols in Human Genetics. Chapter 1:Unit1.14, Analysis of gene-gene interactions.
   Google Scholar
• Johnsen HE, Bergkvist KS, Schmitz A, et al. Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy. Leuk Lymphoma. 2014;55:1251–1260.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Haaber J, Dahl IM, et al. Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica. 2010;95:1730–1737.
   PubMed Web of Science ®Google Scholar
• Vangsted AJ, Klausen TW, Andersen NF, et al. Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004. Eur J Haematol. 2010;85:209–216.
   PubMed Web of Science ®Google Scholar
• Vangsted A, Gimsing P, Klausen TW, et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer. 2007;120:1036–1045.
   PubMed Web of Science ®Google Scholar
• Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res. 1988;16:1215.
   PubMed Web of Science ®Google Scholar
• Saber AT, Nielsen LR, Dictor M, et al. K-ras mutations in sinonasal adenocarcinomas in patients occupationally exposed to wood or leather dust. Cancer Lett. 1998;126:59–65.
   PubMed Web of Science ®Google Scholar
• Bergkvist KS, Nyegaard M, Bøgsted M, et al. Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man. BMC Immunol. 2014;15:3.
   PubMed Web of Science ®Google Scholar
• Henckaerts L, Nielsen KR, Steffensen R, et al. Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit. Crit Care Med. 2009;37:192–201.
   PubMed Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–2028.
   Google Scholar
• Therneau T. A Package for Survival Analysis in S. R package version 2.37-4. 2013. Available from: http://CRAN.R-project.org/package=survival
   Google Scholar
• Bøgsted M, Bilgrau AE, Wardell CP, et al. Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma. PLoS One. 2013;8:e83252.
   PubMed Web of Science ®Google Scholar
• Merico F, Bergui L, Gregoretti MG, et al. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol. 1993;92:27–31.
   PubMed Web of Science ®Google Scholar
• Sharma A, Khan R, Joshi S, et al. Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma. Leuk Lymphoma. 2010;51:920–927.
   PubMed Web of Science ®Google Scholar
• Huizinga TW, Westendorp RG, Bollen EL, et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol. 1997;72:149–153.
   PubMed Web of Science ®Google Scholar
• Bruunsgaard H, Benfield TL, Andersen-Ranberg K, et al. The tumor necrosis factor alpha -308G > A polymorphism is associated with dementia in the oldest old. J Am Geriatr Soc. 2004;52:1361–1366.
   PubMed Web of Science ®Google Scholar
• Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1–8.
   PubMedGoogle Scholar
• Du J, Yuan Z, Zhang C, et al. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Leuk Res. 2010;34:1453–1458.
   PubMed Web of Science ®Google Scholar
• Mazur G, Bogunia-Kubik K, Wróbel T, et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett. 2005;96:241–246.
   PubMed Web of Science ®Google Scholar
• Munro LR, Johnston PW, Marshall NA, et al. Polymorphisms in the interleukin-10 and interferon gamma genes in Hodgkin lymphoma. Leuk Lymphoma. 2003;44:2083–2088.
   PubMed Web of Science ®Google Scholar
• Nielsen AR, Plomgaard P, Krabbe KS, et al. IL-6, but not TNF-α, increases plasma YKL-40 in human subjects. Cytokine. 2011;55:152–155.
   PubMed Web of Science ®Google Scholar
• Nielsen KR, Steffensen R, Boegsted M, et al. Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Res Ther. 2011;13:R109.
   PubMed Web of Science ®Google Scholar